Singapore markets close in 7 hours 33 minutes
  • Straits Times Index

    3,257.99
    -25.36 (-0.77%)
     
  • Nikkei

    27,113.13
    -475.24 (-1.72%)
     
  • Hang Seng

    24,656.46
    0.00 (0.00%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • BTC-USD

    36,087.52
    +109.62 (+0.30%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • S&P 500

    4,410.13
    +12.19 (+0.28%)
     
  • Dow

    34,364.50
    +99.13 (+0.29%)
     
  • Nasdaq

    13,855.13
    +86.21 (+0.63%)
     
  • Gold

    1,842.60
    +0.90 (+0.05%)
     
  • Crude Oil

    83.64
    +0.33 (+0.40%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • FTSE Bursa Malaysia

    1,514.87
    -6.99 (-0.46%)
     
  • Jakarta Composite Index

    6,655.17
    -71.21 (-1.06%)
     
  • PSE Index

    7,252.64
    -40.88 (-0.56%)
     

Why NRx Pharmaceuticals Stock Soared Today

·1-min read
Why NRx Pharmaceuticals Stock Soared Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GILD

Shares of NRx Pharmaceuticals (NASDAQ: NRXP) surged on Monday after the healthcare company released promising clinical trial data for its investigational COVID-19 treatment, aviptadil. An analysis conducted by respected statistician Dr. David Schoenfeld found that patients treated with aviptadil had a significantly higher probability of recovering from critical COVID-19 and respiratory failure than those who received existing therapies. Among those who previously received Gilead Sciences' (NASDAQ: GILD) remdesivir, patients treated with aviptadil were 2.5 times more likely to be alive and free of respiratory failure at 60 days than those who received a placebo.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting